Get the Stockscreener App
64.78
3.76%
+2.35
Janux Therapeutics Inc stock is currently priced at $64.78, with a 24-hour trading volume of 1.05M.
It has seen a +3.76% increased in the last 24 hours and a +78.26% rose in the past month.
The chart indicates a potential bullish trend, as the stock is above the $61.21 pivot point. If it approaches the $66.01 resistance level, significant changes may occur.
Previous Close:
$62.43
Open:
$63.98
24h Volume:
1.05M
Market Cap:
$3.36B
Revenue:
$8.08M
Net Income/Loss:
$-58.29M
P/E Ratio:
-39.74
EPS:
-1.63
Net Cash Flow:
$-52.43M
1W Performance:
+36.70%
1M Performance:
+78.26%
6M Performance:
+856.87%
1Y Performance:
+331.87%
1D Range:
$59.31
$65.60
52W Range:
$5.65
$65.60
Janux Therapeutics Inc Stock (JANX) Company Profile
Name
Janux Therapeutics Inc
Sector
Industry
Phone
858-750-4700
Address
11099 North Torrey Pines Road, Suite 290, La Jolla
Janux Therapeutics Inc Stock (JANX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-06-23 | Initiated | Wedbush | Outperform |
| Nov-14-22 | Initiated | William Blair | Outperform |
Janux Therapeutics Inc Stock (JANX) Latest News
Here's What Could Help Janux Therapeutics (JANX) Maintain Its Recent Price Strength
Zacks Investment Research
A Glimpse Into The Expert Outlook On Janux Therapeutics Through 6 Analysts
Benzinga
Janux (JANX) Rises Almost 50% in a Week on Buyout Rumors
Zacks Investment Research
Janux Therapeutics (JANX) is on the Move, Here's Why the Trend Could be Sustainable
Zacks Investment Research
Why Janux Therapeutics Stock Is Crushing It This Week
The Motley Fool
Why Fastenal Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Benzinga
Janux Therapeutics Inc Stock (JANX) Financials Data
Janux Therapeutics Inc (JANX) Revenue 2024
JANX reported a revenue (TTM) of $8.08 million for the quarter ending December 31, 2023, a -6.14% decline year-over-year.
Janux Therapeutics Inc (JANX) Net Income 2024
JANX net income (TTM) was -$58.29 million for the quarter ending December 31, 2023, a +7.56% increase year-over-year.
Janux Therapeutics Inc (JANX) Cash Flow 2024
JANX recorded a free cash flow (TTM) of -$52.42 million for the quarter ending December 31, 2023, a -6.19% decrease year-over-year.
Janux Therapeutics Inc (JANX) Earnings per Share 2024
JANX earnings per share (TTM) was -$1.33 for the quarter ending December 31, 2023, a +12.50% growth year-over-year.
About Janux Therapeutics Inc
Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. It is also developing a Tumor Activated Immunomodulator (TRACIr) costimulatory bispecific product candidate against programmed death-ligand 1 and CD28 designed to improve the anti-tumor activity of T cells. The company was incorporated in 2017 and is headquartered in La Jolla, California.
1.62%
0.15%
Cap:
|
Volume (24h):